CRISPR’s not on the cusp of anything.

"How many diseases could humans treat if the DNA in troublesome cells could be edited within the body? Half? Most? How about “absolutely everything”? That was the answer Irina Conboy, a bioengineer at U.C. Berkeley, recently gave to New Scientist. Her optimism illustrates the promise, announced three years ago, of CRISPR-Cas9—the new tool scientists have to edit the genome directly, quickly, and cheaply...

CRISPR’s not on the cusp of anything.

"How many diseases could humans treat if the DNA in troublesome cells could be edited within the body? Half? Most? How about “absolutely everything”? That was the answer Irina Conboy, a bioengineer at U.C. Berkeley, recently gave to New Scientist. Her optimism illustrates the promise, announced three years ago, of CRISPR-Cas9—the new tool scientists have to edit the genome directly, quickly, and cheaply...